Advertisement Pharmaceutical Business review - Page 2 of 5236 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
April 21, 2025

US FDA clears Calidi’s CLD-201 for clinical development in solid tumours

The US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for CLD-201, an allogeneic stem cell-based immunotherapy developed by Calidi Biotherapeutics, set to advance into clinical development for solid tumours.

Continue
The trials will assess the therapy’s safety, tolerability, and initial effectiveness in patients with challenging cancers. Credit: National Cancer Institute by Unsplash.
April 17, 2025

Glycomine secures $115m funding for Phase IIb trial of rare disease drug

PMM2-CDG stems from a genetic mutation in the PMM2. Credit: Braňo on Unsplash.
April 16, 2025

Norgine agrees to acquire Theravia

The acquisition is expected to be a primary growth driver for Norgine in the medium to long term. Credit: National Cancer Institute on Unsplash.

Contracts

January 23, 2025

Kamada to supply immune globulin products in Latin America

KAMRAB must be administered alongside a complete rabies vaccine regimen. Credit: Nappy on Unsplash.

Bavarian Nordic secures $156.8m US vaccine deal

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Deals

Deals January 20, 2025

Fermion and Simcere to partner on development of pain treatment drug

Pharmaceutical Business Review

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Popular

  1. INmune Bio, CGT Catapult to set up manufacturing for cell therapy platforms
  2. Nona Biosciences and Atossa team up to discover breast cancer therapies
  3. Imbria secures $57.5m to advance ninerafaxstat through Phase IIb nHCM trial
  4. Renovaro closes merger transaction with BioSymetrics
  5. France 2030 funds 4MB’s knee osteoarthritis drug trial

PRESS RELEASES

LTS Wins Funding from BARDA’s Patch Forward Prize Competition for Two artnerships
LTS Wins Funding from BARDA’s Patch Forward Prize Competition for Two artnerships
Gerresheimer Delivers Solid Results in the Financial Year 2024 Despite Market Headwinds
Gerresheimer Delivers Solid Results in the Financial Year 2024 Despite Market Headwinds
Two Stories, One Future: Gerresheimer and Bormioli Pharma at Pharmapack 2025
Two Stories, One Future: Gerresheimer and Bormioli Pharma at Pharmapack 2025
Gerresheimer Successfully Completes Acquisition of Blitz LuxCo, the Holding Company of the Bormioli Pharma Group
Gerresheimer Successfully Completes Acquisition of Blitz LuxCo, the Holding Company of the Bormioli Pharma Group
Gerresheimer Builds New Production Capacities for Glass Syringes at Skopje Site
Gerresheimer Builds New Production Capacities for Glass Syringes at Skopje Site

Suppliers

Whitepapers

Saving Through Partnership and Innovation
Saving Through Partnership and Innovation
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Wound Care – Selecting the Right Antiseptic for Your Formulation
Wound Care – Selecting the Right Antiseptic for Your Formulation